Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241

Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

Published:2016-10-11 Issue:11 Volume:39 Page:e198-e198
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Agrawal Sweety¹,Gupta Yashdeep¹

Affiliation:

1. Department of Endocrinology & Metabolism, All India Institute of Medical Sciences, New Delhi, India

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/39/11/e198/544413/dc161340.pdf

Reference3 articles.

1. Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies;Kazda;Diabetes Care,2016

2. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice;Sørensen;Diabetes,2006

3. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes;Kelly;Diabetes Obes Metab,2015

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Should metformin remain the first-line therapy for treatment of type 2 diabetes?;Therapeutic Advances in Endocrinology and Metabolism;2021-01

2. Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics;Drugs;2020-09-15

3. Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism;Clinical Medicine Insights: Endocrinology and Diabetes;2020-01

4. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”;Journal of Nephrology;2019-10-02

5. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus;Nature Reviews Endocrinology;2019-08-22